Cong PF, Qu YC, Chen JP, Duan LL, Lin CJ, Zhu XL, Li-Ling J, Zhang MX. Growth inhibition and apoptosis induction by alternol in pancreatic carcinoma cells. World J Gastroenterol 2015; 21(15): 4526-4535 [PMID: 25914461 DOI: 10.3748/wjg.v21.i15.4526]
Corresponding Author of This Article
Mei-Xia Zhang, PhD, Professor, Laboratory of Metabolic Disease Research and Drug Development, China Medical University, 77 Puhe Road, Shenyang North New Area, Shenyang 110122, Liaoning Province, China. zhangmeixia@mail.cmu.edu.cn
Research Domain of This Article
Oncology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Pei-Fang Cong, Ying-Chun Qu, Cheng-Jiang Lin, Xiao-Lin Zhu, Mei-Xia Zhang, Laboratory of Metabolic Disease Research and Drug Development, China Medical University, Shenyang 110122, Liaoning Province, China
Jie-Peng Chen, Li-Li Duan, Strand Biotechnology Institute of Research, Shantou 515041, Guangdong Province, China
Jesse Li-Ling, Nanchuan Institute of Biological Research, Joint Key Laboratory for Bio-resource Research and Utilization of Sichuan and Chongqing, Chongqing 408400, China
Author contributions: Zhang MX and Li-Ling J designed the study and take responsibility for the integrity and accuracy of the data analysis; Cong PF, Qu YC, Lin CJ and Zhu XL conducted the study; Chen JP and Duan LL performed the data analysis; Zhang MX and Li-Ling J wrote the manuscript and are responsible for its originality and consistency.
Supported by Natural Science Foundation of China, No. 81072899, Natural Science Foundation of Liaoning Province, No. 2013021081 and Natural Science Foundation of Chongqing, No. cstc2013jcyjA1587.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Mei-Xia Zhang, PhD, Professor, Laboratory of Metabolic Disease Research and Drug Development, China Medical University, 77 Puhe Road, Shenyang North New Area, Shenyang 110122, Liaoning Province, China. zhangmeixia@mail.cmu.edu.cn
Telephone: +86-24-83782093 Fax: +86-24-83782093
Received: September 10, 2014 Peer-review started: September 14, 2014 First decision: October 14, 2014 Revised: November 11, 2014 Accepted: January 8, 2015 Article in press: January 8, 2015 Published online: April 21, 2015 Processing time: 222 Days and 6 Hours
Abstract
AIM: To investigate the effect of alternol on pancreatic cancer cells.
METHODS: Pancreatic cancer cells PANC-1 and BxPC3 were treated with various concentrations of alternol for 24, 48 and 72 h. Cell proliferation was measured by cell counting. Cell cycle distribution and mitochondrial membrane potential were determined by flow cytometry. Apoptosis was determined by a TdT-mediated dUTP nick end labeling assay and Hoechst staining. Expression of caspase 3, Bcl-2, p53 and p21 was measured by western blotting.
RESULTS: Alternol showed dose- and time-dependent inhibition of the proliferation of PANC-1 and BxPC3 cells in vitro. Alternol induced apoptosis and cell cycle arrest at S phase and decreased mitochondrial membrane potential. Alternol activated caspase 3, upregulated p53 and p21 expression, and downregulated Bcl-2 expression in a dose-dependent manner.
CONCLUSION: Our results suggested that alternol is a candidate for treatment of pancreatic cancer.
Core tip: Pancreatic cancer is an aggressive disease with a 5-year survival < 5%. Alternol has shown anti-cancer activity against various types of cancer cells. The aim of this study was to investigate the effect of alternol on pancreatic cancer cells. Alternol inhibited proliferation of PANC-1 and BxPC3 cells. It induced apoptosis and cell cycle arrest and decreased mitochondrial membrane potential. Alternol activated caspase 3, upregulated p53 and p21 expression, and downregulated Bcl-2 expression. In summary, we concluded that alternol may provide an effective regimen for the treatment of pancreatic cancer.
